Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för amrubicin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2020-06-23

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.

Igawa S, Ono T, Kasajima M, Manabe H, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K.

Cancer Manag Res · research-article; journal article · DOI 10.2147/cmar.s255552

Bibliografisk träff 2020-06-01

Efficacy of weekly amrubicin for refractory or relapsed non-small cell lung cancer: A protocol of systematic review and meta-analysis.

Dang D, Jiang C, Xie MR.

Medicine (Baltimore) · review-article; journal article · DOI 10.1097/md.0000000000020454

Bibliografisk träff 2020-05-28

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.

Ikeda T, Takemoto S, Senju H, Gyotoku H, Taniguchi H, Shimada M, Dotsu Y, Umeyama Y, Tomono H, Kitazaki T, Fukuda M, Soda H, Yamaguchi H, Fukuda M, Mukae H.

Thorac Cancer · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1111/1759-7714.13490

Bibliografisk träff 2020-05-13

Effective treatment of relapsed prostate small cell carcinoma with amrubicin: report of a case.

Kobayashi K, Muto M, Shigematsu Y.

Int Cancer Conf J · journal article; case reports; case-report · DOI 10.1007/s13691-020-00416-4

Bibliografisk träff 2020-01-03

Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.

Sakurai R, Kaira K, Miura Y, Sunaga N, Saito R, Oyama T, Hisada T, Yamada M.

Thorac Cancer · research-article; journal article · DOI 10.1111/1759-7714.13289

Bibliografisk träff 2019-10-03

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.

Makino Y, Makihara-Ando R, Ogawa T, Sato H, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Ohe Y, Yamamoto N.

Cancer Sci · research-article; journal article · DOI 10.1111/cas.14194

Bibliografisk träff 2019-09-18

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.

Hellyer JA, Gubens MA, Cunanan KM, Padda SK, Burns M, Spittler AJ, Riess JW, San Pedro-Salcedo M, Ramchandran KJ, Neal JW, Wakelee HA, Loehrer PJ.

Lung Cancer · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.lungcan.2019.09.015

Bibliografisk träff 1998-10-01

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y.

Jpn J Cancer Res · research-article; journal article · DOI 10.1111/j.1349-7006.1998.tb00498.x